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Chapter 1: Overview of General Anesthetics Use in Infants 
 
Abstract: General anesthetics act by either blocking N-methyl-d-aspartate (NMDA) receptors or 
over stimulating γ-aminobutyric acid (GABA) receptors.1–3 The actions of these receptors are 
responsible for the anesthetized state and are also crucial in the neurological development of 
infants.2,4–8 Animal studies, although limited, provide vital information about general 
anesthesia’s neurotoxicity its hindrance of neurological development. Exposure to general 
anesthesia can severely hinder proper neuronal migration, synaptogenesis, and can drastically 
increase neuronal apoptosis in infant animals.9–16 General anesthetics are more neurotoxic to 
infant animals in combination compared to individually.10,16,17 Additionally, multiple exposures 
to general anesthesia tend to have compounding deleterious effects on neurological development 
in infant animals.12 It is likely that repeated exposure and combinational exposure to general 
anesthetics are the most detrimental to neurological development. Many retrospective studies on 
human infants show a correlation between exposure to general anesthesia and an increased risk 
of neurodevelopment disorders.18–25 However, these studies are statistically limited due to 
confounding factors. These confounding factors are the reason direct evidence of the neurotoxic 
effects of general anesthetics has been so elusive. In vitro human stem cell models provide an 
ethical alternative to clinical studies. However, clinical trials are necessary and are the most 
promising methods for obtaining direct evidence of the deleterious effects of general anesthesia 
on the developing human brain. Different methods used in clinical trials on infants help to 
minimalize ethical dilemmas, increase recruitment rates, and maximize safety and expediency. 
Specifically, this paper will evaluate the efficacy and safety of different methods used in clinical 
trials and will propose how clinical trials can be designed for future studies. 
 
How General Anesthesia Works 
According to the 2004 National Hospital Discharge Survey, approximately three million 
children in the United States undergo surgical procedures that require general anesthesia.26 This 
does not include children that require general anesthesia for nonsurgical purposes such as dental 
procedures or imaging studies. A large portion of these children are infants when they are first 
exposed to general anesthesia. This fact is concerning considering that many general anesthetics 
exhibit neurotoxicity in infant animals (including non-human primates). Furthermore, 
retrospective studies demonstrate that children requiring surgery as infants have lower cognitive 
performance than children who did not require surgery.20–22,24,25 Unfortunately, many have 
criticized this data claiming that these studies could be irrelevant due to confounding factors. 
The concern for the long-term neurological effects of general anesthesia on infants 
prompted the FDA in 2007 to look into the data concerning general anesthesia’s neurotoxicity.26 
The FDA determined that no changes could be made to which general anesthetics are 
administered to infants based on current evidence.26,27 However, they urged that more 
comprehensive and conclusive clinical studies be conducted promptly to determine which 
general anesthetics were neurotoxic to infants or children.26,27 The FDA also recommended that 
purely elective surgery be deferred to after 6 months of age at a minimum.26,27 Clinical studies in 
infants are crucial considering how long the critical period of neurological development lasts. 
General anesthetics have been shown to have the most severe detrimental effects on neurological 
development in animals during critical periods known as synaptogenesis.9,10,28 The length of 
synaptogenesis in humans lasts from approximately the second trimester of pregnancy to three 
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years after birth.21,25,28–30 This is troubling considering many surgical procedures on infants 
require general anesthesia. 
The two broad classes of anesthesia are local and general. Local anesthetics work by 
blocking neural pain signals in a specific site of the body.31 General anesthetics alter the function 
of neurons in the central nervous system (CNS) by directly interacting with multiple ion 
channels.31 These ion channels control the excitability of neurons by regulating the flow of ions. 
An excitatory effect is caused by the neuron depolarizing.31 An inhibitory effect is caused by the 
neuron hyperpolarizing.31 The flow of ions (and therefore the polarization of the neuron) is 
determined by the anesthetic agent.  
The six general anesthetics that are commonly used in pediatric care fall into two 
categories: inhalational and intravenous. The inhalational general anesthetics are nitrous oxide, 
isoflurane, sevoflurane, and desflurane.31 These are called inhalational anesthetics because they 
are administered through a respirator. The intravenous general anesthetics are propofol and 
ketamine, which are administered directly into the blood stream.31 General anesthetics act by 
either blocking N-methyl-d-aspartate (NMDA) receptors or over-activating γ-aminobutyric acid 
(GABA) receptors.1–3 The NMDA receptor is a primary excitatory neurotransmitter receptor in 
the CNS.32 The GABA receptor is the most abundant fast inhibitory neurotransmitter receptor in 
the CNS.31 The two modes of action for general anesthetics are blocking excitatory signals or 
enhancing inhibitory signals.31 Ketamine and nitrous oxide primarily act through blocking 
NMDA receptors.2,31 However, they also over-activate GABA receptors but to a lesser degree 
than other general anesthetics. Isoflurane, sevoflurane, desflurane, and propofol act primarily by 
over-activating GABA receptors.31 
The deleterious effects of ethanol on the developing brain are due to ethanol blocking 
NMDA receptors and over-activating GABA receptors.33 Ethanol is known to cause severe 
neurological developmental disorders in fetuses, such as fetal alcohol syndrome, when ingested 
by the mother during pregnancy.33–35 Pregnant women are warned to stay away from alcohol 
throughout their entire pregnancy due to the risk of fetal alcohol syndrome. Unfortunately, many 
pregnant women or infants cannot be withheld from general anesthesia if surgery is required due 
to its necessity for most surgical procedures. Since general anesthesia is essential, it is extremely 
important to understand how different general anesthetics affect the developing brain in order to 
prevent developmental impairment in infants. 
 
Effects of Blocking NMDA and Over-activating GABA 
There are several reasons why blocking NMDA receptors and over-activating GABA 
receptors hinder neurological development. The developing brain goes through critical periods 
where GABA receptors are stimulated by NMDA receptors.2,7,8 GABA receptors need to be 
stimulated in the developing brain in order for immature neurons and oligodendrocytes to mature 
properly.36 Stimulation of GABA receptors also strengthens NMDA receptor stimulation and is 
vital in the formation of neural networks.4–7 This period of brain development is called 
synaptogenesis because new synapses or neuronal connections are being formed.28,37 
Connections that are not stimulated are deemed unnecessary by the body and are removed 
through a process known as synaptic pruning.38 This process allows poorly stimulated neurons  
to go through apoptosis throughout neurodevelopment.4,5 This is one reason why strengthening 
neural networks through proper stimulation is so vital to normal neurodevelopment. A study in 
mice showed that neurons do not migrate properly to form neural networks when NMDA 
receptors are not expressed.39 This same study showed that increasing NMDA receptor 
Page 4 
expression increased neuronal migration and neural network formation.39 The NMDA receptor is 
known to be vital to learning and memory.32 Therefore, it is likely that hindered synaptogenesis 
or neuronal migration may impair learning and memory. 
The proximity of NMDA and GABA receptors allows them to synergistically initiate key 
events in neurological developmental. A study in infant mice found that GABA receptor density 
was 90 times higher around NMDA receptors than in other parts of the brain.8 These receptors 
work in combination to achieve synchronous 
synaptic activity.8 Synchronous synaptic activity 
occurs when neurons are rhythmically stimulated 
with other neurons in the same neural network.8,40 
Synchronous synaptic activity is vital to proper 
neurological development and neural network 
formation.8,41 A study on rat neurons in vitro 
found that synchronous synaptic activity led to the 
maturation of immature synapses through the 
addition of AMPA receptors to synapse containing 
the NMDA receptor.40 The addition of AMPA 
receptors allows NMDA receptors to be 
stimulated.40 AMPA receptors also prevent 
afferent connections from forming later on in 
neurological development.40  
There are serious detrimental 
developmental effects when NMDA receptors are 
blocked. In vivo studies of infant mice and rats 
have shown that the developing brain goes 
through excessive neuroapoptosis when NMDA 
receptors are blocked for hours at a time.2,42,43 
This is in contrast to normal neuroapoptosis that 
occurs in the developing brain during critical 
periods in order to strengthen neural circuits and 
remove unnecessary connections.28 When the 
brain undergoes excessive neuroapoptosis 
during development, there are life-long 
detrimental effects. Learning impairments and 
cognitive disability are common side effects of 
extensive neuroapoptosis during 
neurodevelopment.28 This outcome is not surprising considering that an excessive amount of 
neurons are dying off leading to gaps in neural networks. 
 
Inhalational Anesthesia and Neurological Development 
Antiepileptic drugs have been shown to severely impair cognitive development in infant 
rats.44 One large clinical study looked at the frequency of physical birth defects in babies from 
epileptic mothers who were prescribed antiepileptic drugs. The study found that exposure to 
antiepileptic drugs in utero significantly increased a baby’s risk of being born with physical 
abnormalities including major malformations, microcephaly, growth retardation, and hypoplasia 
Figure 1: Diagram of a Neuron and its 
Structures. Dendritic spines are located on 
the shafts of the dendrites. The synapse is 
formed between the axon of one neuron 
and the dendrite(s) of another neuron.48 
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of the  midface and fingers.45 Antiepileptic drugs act on GABA receptors by over-stimulating 
them in a manner similar to many general anesthetics.44 
Sevoflurane, isoflurane, and desflurane are all inhalational general anesthetics that act by 
over-stimulating GABA receptors.31 Sevoflurane, isoflurane, and desflurane have all been shown 
to alter dendritic spine density on dendritic  shafts in vivo in infant rats after two or more hours 
of exposure.46,47 Dendritic spine shafts are main sites of synaptic connections in neural 
networks.46,47 The dendrites of a healthy neuron (where the dendritic spines are located) can be 
seen in figure 1.48 A primate study demonstrated a 13-fold increase in neuronal apoptosis in 
rhesus macaque brain cells in vitro after five hours of exposure to clinical concentrations of 
isoflurane compared to controls.15 These results are unfortunate considering that isoflurane is 
capable of passing from mother through the placenta into the fetus in humans.49 This indicates 
that mothers who receive isoflurane during cesarean sections are inadvertently exposing their 
unborn babies to a potentially neurotoxic general anesthetic for the duration of the procedure. 
The findings of one in utero study on rats add evidence to the danger of in utero exposure to 
isoflurane. The rats in this study were in a stage comparable to the second trimester of pregnancy 
in humans.9 The rat mothers were exposed to clinical concentrations of isoflurane for four 
hours.9 Babies that were exposed to isoflurane in utero had impaired spatial memory, impaired 
learning, and reduced anxiety compared to control rats.9 These symptoms are most likely signs of 
improper neurological development. 
Studies have found that the use of multiple general anesthetics is actually more 
detrimental than using only one anesthetic.10,16,17 Two studies performed on infant rats using 
clinically relevant concentrations of nitrous oxide and isoflurane showed that these general 
anesthetics used in combination caused severe neuroapoptosis and prevented proper synapse 
formation in developmentally vulnerable regions of the brain.10,17 Specifically, these general 
anesthetics modified synaptic protein levels. These modifications impaired the function of the 
proteins and prevented synaptogenesis.10 This impairment of normal neurological development 
and synapse formation could lead to long-term learning impairments and memory deficits. A 
study involving in utero guinea pigs showed that isoflurane in combination with nitrous oxide, 
compared to isoflurane treatment alone, drastically increased neuronal apoptosis in vulnerable 
brain regions as well.16 These studies indicate that inhalational general anesthetics need to be 
studied further individually before they can safely be used in combination. 
 
Intravenous Anesthesia and Neurological Development 
Propofol is a general anesthetic that acts by over-activating the GABA receptor. Propofol 
has been shown to induce neuroapoptosis and cause learning impairments.11,50 An in vivo study 
on infant mice found that a quarter of the concentration of propofol needed to induce anesthesia 
was sufficient to induce neuronal apoptosis.50 An in vivo study found on infant rats injected with 
clinical concentrations of propofol showed signs of neurodegeneration and had learning 
impairment compared to control rats.11 These are both expected symptoms from GABA over-
activation considering the role of GABA receptors in establishing and strengthening neural 
networks.5,7 
Ketamine is a general anesthetic that acts by blocking the NMDA receptor. Ketamine is 
commonly used in infants during surgical procedures.3 Ketamine has been shown to cause 
extensive neuroapoptosis during synaptogenesis.14,43 An in vivo study on infant rats showed that 
exposure to ketamine significantly increased neuroapoptosis.43 The infant rats were exposed to 
seven doses of ketamine leading to a 28-fold increase in neuroapoptosis compared to controls.43. 
Page 6 
An in vivo study on infant rhesus monkeys showed that exposure to ketamine significantly 
increased necrotic and apoptotic neuronal cell death.14 Additionally, the researchers found that 
messenger RNA for the NMDA was significantly increased in areas that underwent extensive 
cell death.14 Rhesus monkeys that were earlier in development had increased cell death compared 
to rhesus monkeys three weeks further in development.14 It is concerning that several animal 
studies have shown that concentrations of ketamine, propofol or isoflurane that are 
approximately a quarter of that needed for anesthesia still induce neuronal apoptosis in infant 
mice.13,50,51 
The studies done on primitive mammals provide evidence that the negative effects of 
anesthesia on the developing brain are significant. They provoke the need for further research 
into the detrimental effects of anesthesia on human infants. However, the clinical significance of 
the results of these studies is limited. This is due to the fact that the studies were performed on 
primitive mammals. These studies are indicative of neurotoxicity at best and completely 
irrelevant at worst. The data from non-human primate studies are more clinically significant. 
Non-human primate studies are the closest in vivo model that can translate to humans besides 
humans themselves. The agreement in evidence from primitive mammal and non-human primate 
studies is sufficient to begin large scale clinical trials on the effects of general anesthetics on 
infants.   
 
Current Clinical Research on Infants 
Several clinical studies have analyzed the long-term effects of general anesthetics on 
infants. They all show that exposure to general anesthetics in infancy increases the risk of 
neurodevelopmental disorders.18–25 The studies look at infants that required surgery for various 
reasons. They compare the long term neurological development (in areas such as learning, 
memory and motor control) to baseline values determined from infants that did not require 
surgery. The studies assessed neurological development at varying intervals ranging from two to 
ten years after surgery. Collectively, these retrospective studies underscore that infantile 
exposure to general anesthesia significantly increases the risk of learning and memory 
impairment.18–25 The critics of these studies often point out that confounding factors cannot be 
taken into account in these retrospective studies. They claim that this reduces the statistical 
significance of the studies. Due to ethical concerns, many critics are skeptical about relying on 
evidence from retrospective studies and animal studies as a basis for clinical trials on infants. 
The lack of clinical trials leaves doctors lacking accurate information about the safety of 
general anesthetics in infants. This ignorance may lead doctors to inadvertently expose babies to 
general anesthetics that are neurotoxic. This most likely is already happening as was shown in 
the results of one retrospective study. A retrospective study on pregnant women found that 
maternal exposure to general anesthesia during the first trimester increased the risk of babies 
being born with CNS defects.52 Fortunately, a new in vitro system has been developed using 
human stem cells to create a close resemblance to in vivo neurological development.53 This is not 
a perfect system because it does not exactly mimic a true in vivo system. However, it is a step 
forward in the ethical dilemma that surrounds clinical trials in infants. This in vitro system would 
be useful in providing more evidence and data so that clinical trials in infants can proceed. This 
stem cell system would be perfect for testing which general anesthetics are neurotoxic during 
neurological development.53 This would also be extremely effective at determining methods of 
preventing general anesthetics neurotoxic effects.53 
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History of Clinical Research on Infants and Children 
In the 1930s, the use of drugs on children was widely unregulated.54 Children were often 
administered drugs with questionable safety.54 This lead to several adverse events that could 
have been avoided. Due to an ingredient used to manufacture the drug elixir of sulfanilamide, 
almost 100 children died in the late 1930s.54 Consequentially, an amendment was made to the 
Federal Food and Drug Act in 1938 requiring drug ingredients to be labeled honestly and with 
documentation of the drug’s safety.54 Sadly, many of the ethical guidelines and regulations 
behind clinical trials and requirements for human drug testing have come about due to the 
occurrence of severely adverse reactions similar to the example mentioned above.54 
In the 1960s, the drug thalidomide was found to cause massive birth defects and 
malformations.54 This led to the passing of the Harris–Kefauver Amendment to the Food, Drug 
and Cosmetic Act in 1962 which required drugs to be tested on animals before moving to clinical 
trials in humans.54 The ethics of clinical trials have often been difficult to discern, leading to an 
ever-evolving landscape of ethical guidelines, requirements, and practices. 
Informed consent is a perfect example of how greatly ethical guidelines and policies have 
changed over the years. The Supreme Court ruled in January 31, 1944 that parents may be free to 
become martyrs themselves. But it does not follow they are free, in identical circumstances, to 
make martyrs of their children before they have reached the age of full and legal discretion when 
they can make that choice for themselves.55 The implications of this ruling were profound. All 
nontherapeutic clinical research on minors was considered unlawful even if the parents had 
consented. In accordance with the advice from legal experts of the day, this was the stance that 
many government agencies took after this 1944 ruling.55  
This legal stance was largely met with resistance by practicing physicians. In 1967, The 
Royal College of Physicians emphasized the importance that clinical investigations be conducted 
with expediency and little regulation.56 Their main recommendation was that doctors should be 
free of strict government control so as not to defer clinical trials from occurring.56 They express 
their belief that attempting to rigidly control clinical trials would discourage physicians from 
conducting such research.56 This would in turn lead to a stagnation in the advancement of 
medically relevant clinical knowledge. The conflicting stances of the U.S. government and 
medical organizations caused confusion and an ethically difficult situation. The Supreme Court 
ruling had little effect on clinical research in humans. Guidelines and regulations were worded in 
such a way as to indirectly promote the continuance of nontherapeutic clinical research on 
minors. For example, The Royal College of Physicians stated in 1973,  
Clinical research investigation of children… which is not of direct benefit to the 
patient should be conducted, but only when the procedures entail negligible risk 
or discomfort and subject to the provisions of any common and statute law 
prevailing at the time.55 
This statement does not directly contradict the Supreme Court ruling. However, it does infer that 
nontherapeutic clinical research on minors is permissible if it causes negligible harm. The 
problem with this guideline is that it is rather subjective. A physician must use their personal 
discretion when designing and implementing clinical trials. The lack of clear regulation and 
conflicting opinions led to several medical organizations developing their own ethical guidelines 
and requirements. 
The World Medical Association has developed the Declaration of Helsinki over the last 
fifty years. The Declaration of Helsinki is a document that lays out ethical guidelines for how 
clinical trials in humans should be conducted.57,58 The document has become increasingly 
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inclusive and extensive as ethical issues over clinical trials on humans have arisen.59 The 
importance of this document cannot be understated. It has become a standard that is 
internationally recognized in the field of bioethics. The Declaration of Helsinki states that the 
advancement of medical knowledge is brought about through research which must occasionally 
rely on some experimentation involving human patients.57,58 There are several factors that must 
be considered when dealing with humans. For example, the Declaration of Helsinki requires that 
the well-being of the patient take precedence over the advancement of medical knowledge no 
matter how great the benefit.57,58 The foundation of the Declaration of Helsinki was brought 
about, like many other guidelines and regulations, as a result of gruesome events. What some 
scholars believe to be one of the most important revisions occurred in 1975.59 This revision 
required independent committees to review research protocols involving human patients in order 
to promote ethical accountability.59  
Recently, a group of physicians found that up to 90% of drugs given to neonates were not 
used in an authorized manner or were unlicensed.60 This is a frightening statistic because this 
would cause neonates to be at a greater risk of drug toxicity. A study conducted in 1998 found 
that only 36% of drugs given to children were not used in an approved manner.61 Both these 
studies reveal that minors, and especially in neonates, need to be better protected by conducting 
further clinical research. Unfortunately, the lack of knowledge on drugs’ effects on children, 
infants, and neonates is widespread in medicine. The Physicians’ Desk Reference contains dosing 
information based on age, weight, and other criteria. Unfortunately, less than 30% of the entries 
in the Physicians’ Desk Reference have statements that the safety and efficacy of the drug in 
question has not been determined or dosing information for children, infants, or neonates.54 It is 
not ethical to continue to allow these age groups to receive substandard care because of a lack of 
knowledge. 
This is the main reason the European Medicines Agency met in 2006. They conducted a 
workshop that dealt with ways to introduce incentives to researchers in order to promote the 
study of drugs safety and efficacy in children, infants, and neonates.62 The Best Pharmaceuticals 
for Children Act was passed in 2002 to promote a similar type of incentive in the United States. 
The goal of the Best Pharmaceuticals for Children Act was to promote clinical studies of drugs 
used off-label in children, infants, and neonates.63 Since the act’s passing in 2002, the Food and 
Drug Administration (FDA) and the National Institutes of Health (NIH) have been encouraging 
researchers to conduct studies to evaluate the efficacy and safety of the drugs of drugs used off-
label in these vulnerable age groups.63 It is important to understand how drugs are approved for 
clinical trials in humans and what kind of guidelines regulate the clinical trials themselves. 
The Harris–Kefauver Amendment to the Food, Drug and Cosmetic Act (mentioned 
earlier) led to the formation of the investigational new drug (IND) process for testing drug safety 
and efficacy in clinical trials.54 The IND created the basic requirements of how new drugs are 
tested for safety and efficacy even to this day.54 The IND involves three phases of clinical testing 
after the initial preclinical testing. Phase I of the IND involves testing the drug for safety, 
methods of metabolism, and its eventual removal from the body of the patient 
(pharmacokinetics).54 Phase II involves evaluating the drug for efficacy and proper dosage 
according to numerous variables in the patient such as weight and age.54 In phase III, multiple 
clinical trials are conducted in order to compare their results.54 One of the most important 
considerations during a clinical trial is the risk-to-benefit ratio. 
The risk-to-benefit ratio is the amount of risk a patient is exposed to in order to obtain 
any kind of beneficial result.54 This ratio takes into account how much risk the patient is being 
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subjected to compared to how much the patient or medical community will benefit.54 Ethically, 
physicians should attempt to design trials to achieve low risk and high benefit. Unfortunately, the 
nature of the risk-to-benefit ratio makes it rather subjective when implemented.54 Therefore, it is 
up to ethical committees and physicians to ensure the risk-to-benefit ratio is accurate and 
reasonable. 
 
Ethics of Clinical Research on Infants  
A requirement common to all clinical trials (and an especially sensitive topic when 
dealing with infants) is informed consent. Problems arise with informed consent because of 
subjectivity of updating the patient. Informed consent implies that the patient must be educated 
of what clinical experimentation they will be subjected to.64 Additionally, informed consent 
implies that the patient must be educated so that they have a thorough understanding of the 
risks.64 The education aspect of informed consent presents many problems to the physicians 
conducting the clinical research. Education of patients can be time-consuming and counter-
productive, leading to poor recruitment rates. This creates an ethical dilemma for the 
investigating physician. It is often tempting for the investigating physician to bypass the 
educational aspect of informed consent. However, this is a gross violation of the patient’s right to 
autonomy. The right of autonomy   means the patient should have complete control over his or 
her medical care without the coercion of others. The nature of informed consent makes it 
especially difficult when conducting clinical research on infants. 
The ethical dilemmas of informed consent have caused some critics to suggest that the 
informed consent requirement be forgone in incompetent patients. Informed consent is often 
time-consuming and can lead to poor recruitment rates. Therefore, it may often seem that 
informed consent is counterproductive. Critics of informed consent in the case of incompetent 
patients have suggested that ethical committees approve or disapprove clinical trials to take the 
burden off of parents and guardians. However, a study on the parents of neonates involved in 
clinical trials determined that this would be met with great resistance. Over 80% of the parents in 
the study stated that they would be unhappy with not giving informed consent and relying on an 
ethical committee.65 Other critics have suggested that the attending physician should decide 
whether or not to enroll an incompetent patient in a clinical trial. Yet, the same study mentioned 
above found that over 90% of parents said they would be unhappy with the attending physician 
making the decision.65 Other studies have also shown that parents prefer to make decisions over 
their children in regards to clinical trials.66 However, clinical trials involving infants can achieve 
high recruitment rates while still leaving decision-making in the hands of the parents. 
 Written consent appears to be what harms recruitment rates the most for clinical trials 
involving incompetent patients such as infants. It is believed that the anxiety of parents along 
with the inability to fully process all the written consent forms leads to poor participation.65,67,68 
Morally, it is unacceptable for informed consent to be bypassed altogether.69,70 This kind of 
practice would imply that a benefit to society trumps individual rights. However, other methods 
of consent can limit anxiety and provide parents with a better understanding of what their infant 
will be subjected to. It has been suggested that a progressive approach where parents are 
informed throughout the clinical trial will help reduce anxiety and increase recruitment 
rates.65,67,68 Additionally, time constraints can be reduced by delegating responsibilities to 
different members of ethical committees.68 This streamlining of clinical trial processing would 
also assist recruitment rates by giving parents additional time to consider the pros and cons of the 
clinical trial. Streamlining clinical trial processing could also decrease the duration of clinical 
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trials, leading to an increased rate of medical advancement. Clinical trials in infants must also be 
designed in a precautious and safe manner in order to encourage trust and further participation. 
Streamlining clinical trials in infants can only be taken so far. 
There are several factors that must be taken into careful consideration when designing 
clinical trials involving infants. The smaller dosages that are required for infants make them 
more susceptible to drug overdose. Even a small percentage of error in dosages can result in 
seriously adverse reactions due to the limited maturation of organ systems and low body weight 
of infants.71 Additionally, the recommended dosages and infants has to be adjusted in accordance 
with their development. For example, after one to two months the dosage of a particular drug 
may need to be increased to accommodate organ maturation and weight gain.71 Based on this 
understanding, it is important to have extra regulation and precaution when dealing with infants. 
This extra care has been criticized by activists who argue that clinical trials in infants need to be 
conducted in haste. Unfortunately, this criticism is largely misplaced and probably results from a 
lack of understanding concerning the delicate situation of dealing with infants. 
What distinguishes neonates from infants is their age. Infants are generally regarded as 
babies one month to one year old.71 The term neonate is used to describe a baby just after birth 
until they are approximately one month old.71 However, preterm babies are often regarded as 
neonates for longer periods of time due to the immaturity of their organ systems.71 Neonates are 
more vulnerable than infants due to the inability of their organs to metabolize drugs effectively.71 
This is largely because their organs systems are still very immature.62,71 This is also why infants 
are considered less vulnerable than neonates. With this information in mind, it is better to recruit 
infants and neonates at various stages in development in order to obtain the most reliable 
information in regards to drug safety from clinical trials. This particularly important considering 
the age of a baby plays an important role in influencing parental consent and emotions. 
Interestingly, one study found that parents from a lower socio-demographic background 
were more likely to consent to their children being involved in clinical trials.72 Their main 
motivation behind participation was the advancement of society.72 This raises an important 
question. Should physicians seek to further educate parents from a lower socio-demographic 
background or take advantage of their increased participation? Ethically, it is never acceptable to 
exploit a parent who is emotionally distressed over his or her child. However, it is possible that 
parents from a lower socio-demographic background are simply more altruistic and should be 
praised. Either way, physicians must take special care to inform parents from all backgrounds 
and to not exploit parental emotions to bolster recruitment. 
 
Discussion 
The proper stimulation of NMDA and GABA receptors are vital to neurological 
development.2,4–8 These are also the receptors that many general anesthetics act upon.1–3 The 
NMDA and GABA receptors play roles in neural network formation, neuronal migration, and 
SSA.2,4–8,39,40 These and other neurodevelopmental events are important for learning and 
memory.2,4–8 Neurodevelopmental disorders involving learning and memory deficits are expected 
if these receptors are blocked or dysregulated. General anesthetics act by blocking NMDA 
receptors and over-stimulating GABA receptors.1–3 This means that infants exposed to general 
anesthetics can have hindered neurological development during the entire duration of surgery. 
Both animal and clinical studies demonstrate that the earlier the exposure to general anesthetics 
the more detrimental the effect.14,17,25 General anesthetics most likely impair normal neurological 
developmental by blocking stimulation for extended periods of time. NMDA and GABA 
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receptors are important in establishing and strengthening neural networks.4–8  A lack of proper 
stimulation can lead to neuroapoptosis and subsequent gaps in neural networks.28 These gaps 
could likely lead to improper neurological development and negatively impact learning and 
memory in the long-term.  
Animal models have confirmed that several general anesthetics cause neurodevelopment 
disorders by obstructing proper neurological development. Exposure to general anesthesia during 
infancy in animals can cause widespread neuroapoptosis and alterations to various structures in 
the brain and cause learning and memory impairments.9–16 Even a single exposure to general 
anesthesia can drastically increase neuroapoptosis.15 Sevoflurane, isoflurane, and desflurane 
altered dendritic spine density after two or more hours of exposure at clinically relevant 
concentrations.46,47 This is concerning considering the normal duration of surgical procedures on 
infants is longer than two hours. A large number of infants are exposed to detrimental amounts 
of potentially neurotoxic general anesthetics considering the typical duration of surgeries. This 
follows from the fact that general anesthetics are neurotoxic even after short, single exposures.  
Infants that require multiple surgical procedures and exposures to general anesthetics have an 
increased risk of neurological developmental disorders. Animal studies show that multiple 
exposures to general anesthetics significantly impair neurological development and increase 
neuroapoptosis by 28-fold compared to a single exposure.12,43 It is possible that significant 
cognitive impairments are only noticeable in infants that have been exposed to general anesthesia 
multiple times. Multiple exposures to isoflurane have been shown to severely impair memory 
and cause severe learning deficits.12 This suggests that multiple exposures to GABA receptor 
agonists can compound the negative effects of general anesthetics on neurological development.  
Multiple exposures to general anesthesia causes repeated over-activation of GABA receptors and 
blockade of NMDA receptors. This could have compounding effects leading to more severe 
neural network degradation by neuroapoptosis. 
Unfortunately, many infants that have to go through multiple surgical procedures possess 
other developmental disorders that are seen as confounding factors. These confounding factors 
limit the statistical significance of the study. However, it is possible that the confounding factors 
are distorting the data and leading to an inaccurately low level of reported neurological disorders 
due to general anesthesia. In infant rats, multiple exposures to isoflurane drastically increased 
cognitive and developmental impairment compared to a single exposure.12 It is unfortunate that 
the circumstances that bring a baby into the operating room multiple times for surgery may be 
seen as a confounding factor. This could be why it has been difficult to directly link general 
anesthesia exposure to cognitive and developmental impairment in human infants. 
Several studies have found that the use of multiple general anesthetics is actually more 
detrimental than using only one anesthetic.10,16,17 This data indicates that general anesthetics need 
to be studied further individually before they can safely be used in combination in infants. 
Individual studies would be useful for providing information about why general anesthetics 
hinder neurological development and cause extensive neuroapoptosis. The in vitro human stem 
cell system is a tool that could prove immensely useful in this regard. While it is not a perfect 
replica, the in vitro system does model early neurological development and can ethically be used 
in studies.53 This is a more ethical solution than testing various combinations of general 
anesthetics on human infants. This system could also be used to determine useful prevention 
strategies to combat the neurotoxic effects of general anesthetics on infants. The necessity of 
general anesthetics on infants requires that all possible avenues be pursued. Retrospective studies 
are also ethically acceptable and useful. The key to retrospective studies is to minimalize 
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confounding factors in order to interpret data that is statistically strong. Ethical concerns make 
studying the effects of general anesthesia on infants difficult. However, they are still necessary to 
prevent further exposure of infants to neurotoxic general anesthetics. Currently, controlled 
clinical trials on the effects of general anesthetics on infants are underway. Hopefully, when they 
are complete they will provide clinical insight in preventing general anesthesia induced 
neurological disorders in infants undergoing surgery. It is likely that these trials will (at the very 
least) reveal that repeated exposure and combinational exposure to general anesthetics are the 
most detrimental to neurological development. 
Clinical trials on infants are controversial and raise several ethical dilemmas. Concerns 
over the extent of informed consent and safety of the infants has made extensive ethical 
guidelines for clinical trials a necessity. Regulations and ethical guidelines have largely been 
shaped by adverse reactions and gruesome events. There has been increasing inclusiveness in 
ethical guidelines to ensure that all interest groups are being equally attended to. However, 
heavily regulating clinical trials on infants can delay findings and lower recruitment rates. This 
raises ethical issues over how informed parents should be and how expediently these trials 
should be conducted or approved. There are techniques and methods that can be employed to 
maximize participant safety while bolstering recruitment rates and expediency. For example, 
written consent can lead to poor recruitment rates and should not be used. Instead, parents should 
be informed continually as the clinical trial progresses. Trial design is crucial in this aspect 
because it allows medical knowledge to advance at a reasonable rate so that treating neonates 
and infants becomes safer and more effective. Without these types of clinical trials, physicians 
would not have sufficient evidence to show that they are helping instead of harming an infant. 
However, it is best for physicians to err on the side of precaution in all human clinical trials, 
especially when dealing with neonates and infants.  
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Chapter 2: The Effects of GABA and its Receptor 
 
Introduction 
GABA is the predominant inhibitory neurotransmitter in the CNS of mammals.31,73 
GABA is an atypical neurotransmitter in regards to its biosynthesis and its effects on other 
neurotransmitter concentrations.74 For example, most neurotransmitters rely heavily on recycling 
and reuptake after they have produced their effect.74 However, the recycling of GABA is not as 
important as synthesis of new GABA.74 The receptor for GABA has two main subtypes, GABAA 
and GABAB. The GABAA and GABAB receptors are ubiquitous inhibitory neurotransmitter 
receptors in the CNS, found on almost all cortical neurons.31,73 The NMDA and AMPA receptors 
work in conjunction with GABA receptors and will be briefly discussed in this chapter. 
However, the main focus of this chapter will be on the GABAA receptor due to its important role 
in neurodevelopment. 
 
GABA Synthesis and Catabolism 
The precursor to GABA is glutamic acid (also known as glutamate when negatively 
charged).75 The new synthesis of GABA requires neurons to have a supply of glutamate which 
they are not reliant on de novo glutamate synthesis.75 This requires neurons to import glutamate 
or glutamine, which can be converted by neurons to glutamate.75 Not surprisingly, neurons that 
release GABA express transporters for the import of glutamate and glutamine.76,77 
Glutamine synthetase is the enzyme responsible for converting glutamate to glutamine.75 
Glutamine synthetase is expressed in astrocytes which subsequently release this newly converted 
glutamine to be taken up by GABA releasing neurons.75 The conversion of glutamate to 
glutamine helps to detoxify ammonia and recycle neurotransmitters for inhibitory and excitatory 
neurotransmission.75 In GABA releasing neurons, glutaminase type I (GLS1) is the enzyme 
responsible for the conversion of glutamine back to glutamate.75 The enzyme glutamic acid 
decarboxylase (GAD) is responsible for the conversion of glutamate to GABA.75 After GABA 
has been synthesized, it is moved to synaptic vesicles to be released into the synapse.74 
Expectantly, inhibiting GAD reduces the amount of GABA containing vesicles released into the 
synapse.78 
Neurons are capable of undergoing glucose metabolism including the citric acid cycle. 
Glutamate can be synthesized from the citric acid cycle intermediate α-ketoglutarate.75 However, 
this has minimal contribution to glutamate pools in GABA releasing neurons.75 Blockade of both 
GABA synthesis and degradation reduces the amount of GABA-containing vesicles that are 
released into the synapse.79 Interestingly, blockade of GABA reuptake by GABA transporters 
does not affect the amount of GABA-containing vesicles that are released.79 Taken together, this 
suggests that GABA reuptake is more important for its ability to enter the citric acid cycle than 
to be reused as a neurotransmitter. 
The excitatory amino acid transporter-3 (EAAT3) is expressed at the terminals of neurons 
that release GABA. The EAAT3 allows these neurons to reuse glutamate by importing it back 
into the cell for GABA synthesis. Sodium coupled neutral amino acid transporter 1 and 2, termed 
SNAT1 and SNAT2 respectively, allow neurons to import glutamine. Astrocytes express 
EAAT2 which has a similar function to EAAT3. 
GABA is broken down by the enzyme GABA transaminase (GABA-T).75 GABA-T 
removes and amino group converting GABA into succinc semialdehyde (SSA).75 SAA is further 
degraded into succinate by the enzyme SSA dehydrogenase.75 Succinate can then enter the citric 
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acid cycle. This breakdown of GABA allows neurons to compensate for the citric acid cycle 
intermediate α-ketoglutarate that is used to synthesize GABA. An excellent image representing 
the metabolism of GABA can be seen in figure 2.75 
 
GABAA and Other 
Receptors  
As one of the earliest 
synapse systems to form, the 
importance of the GABAA 
receptor and its substrate to 
neurodevelopment cannot be 
stressed enough.80 Over-
activating GABAA receptors 
results in widespread 
inhibition throughout the brain 
that can be detrimental during 
critical periods such as 
synaptogenesis. GABAA 
receptors must be properly 
stimulated in order for 
immature or undifferentiated 
neurons to mature 
appropriately.36 The NMDA 
receptor is also greatly 
affected by the activation of 
the GABAA receptor. Since the 
NMDA receptor is one the 
most widespread excitatory 
receptors and GABAA is one of 
the most widespread inhibitor 
receptors, they are intrinsically 
related in the formation of 
neural networks.2,7,8 Neural networks cannot properly form without inhibition and stimulation 
induced by the GABAA and NMDA receptor respectively.4–8 Synaptogenesis also relies on the 
actions of both receptors. Unsurprisingly, there are gaps in neural networks when the NMDA and 
GABAA receptors are inhibited or over-activated respectively.28 This is due to the fact that 
during synaptogenesis neurons that are not stimulated or “used” get removed by undergoing 
apoptosis.4,5 This has concept has been termed synaptic pruning and is most likely the main 
neurodevelopmental process affected by general anesthetics.38 
Other receptors are also important in neurodevelopment including the AMPA receptor. 
The GABAA and NMDA receptors are located in close proximity to each other. However, 
AMPA receptors are located essentially right on top of NMDA receptors and affect their signal 
processing.40 In order for neurons to fire in coherent patterns, termed synchronous synaptic 
activity, synapses containing the NMDA receptor must have AMPA receptors added to them.8,40 
The AMPA receptors allow NMDA receptors to become activated by their ligands.40 After 
AMPA receptors are activated, GABA and NMDA receptors must work cooperatively to achieve 
Figure 2: GABA Metabolism. The import of substrates 
needed for GABA synthesis (top left), the transport of 
GABA to the synapse (bottom middle), and the reuptake 
of GABA for further use (top right) are all shown in this 
figure. Relevant abbreviations are mentioned in the text 
above.75 
Page 15 
synchronous synaptic activity.40 This developmental process helps to strengthen necessary 
connections within neural networks and remove unnecessary connections.8,40 
 
Effects of Receptors 
 
The GABAA receptor activity is largely controlled by cation-chloride cotransporters 
(CCC). Binding of GABA to the GABAA receptor can result in propagation or inhibition of a 
signal. What determines the fate of the signal is the concentration of chloride ions, which can 
pass through the receptor 
upon GABA binding. CCCs 
are responsible for 
controlling cellular 
concentrations of sodium 
and potassium. A specific 
type of CCC, the 
sodium/potassium/chloride 
cotransporter (NKCC1) 
increases the chloride 
concentration inside the 
cell.81 NKCC1 imports 
sodium and potassium with 
their concentration gradient 
to force the chloride ions 
against their concentration 
gradient.81 The binding of 
GABA to the GABAA 
receptor causes an efflux of 
chloride ions resulting in 
depolarization.81 
Depolarization results in a propagation of a signal from one neuron onto others. In contrast, the 
CCC potassium/chloride cotransporter 2 (KCC2) decreases the chloride concentration inside the 
cell.81 The KCC2 uses potassium to remove chloride ions from inside the cell.81 The binding of 
GABA in this scenario causes an influx of chloride ions resulting in hyperpolarization.81 
Hyperpolarization results in the reduction of a signal and essentially inhibits signal transduction 
from one neuron to the next. This is how CCCs help to regulate GABAA receptor mediated 
inhibition.81 An excellent figure depicting these interactions can be seen in figure 3.81  
The NMDA receptor is essentially the opposite of the GABAA receptor, which is an anion 
channel. The NMDA receptor is a cation channel that controls the flow of sodium and calcium 
ions into the cell.82–84 The main ligands for the NMDA receptor are glycine and glutamate. 82–84 
Upon binding to glycine and glutamate, the NMDA receptor becomes depolarized resulting in 
signal propagation.82–84 The binding of glycine and glutamate causes the NMDA receptor to open 
allowing the influx of positively charged ions including sodium but especially calcium.82–84 This 
high permeability to calcium makes the NMDA receptor rather unique.82–84 
Figure 3: Cation-Chloride Transporters. This is a figure 
depicting the GABAA receptor and how the flow of ions is 
affected by its absence (a, c) and upon binding (b, d).81  
Another novel feature of the N
preventing depolarization.82–84 When NMDA receptors are stimulated for too long of a period, 
the high amount of calcium influx can affect cellular viability.
happen when general anesthetics are 
administered. Instead, general 
anesthetics that are NMDA antagonists, 
such as isoflurane and nitrous oxide, 
result in an increase in NMDA receptor 
expression.83 The increased density of 
the NMDA receptor results in greater 
stimulation upon neurotransmitter 
release from the pre-synaptic neuron.
This can result in an influx of calcium 
that is virtually identical to excessive 
stimulation and can ultimately induce 
apoptosis.85 
The AMPA receptor (like the 
GABA and NMDA  receptors) is an 
ionotropic receptor, meaning it forms an 
ion pore within the membrane.83 
AMPA receptor allows the influx of 
sodium, potassium, and in some 
instances calcium.83 The AMPA recep
is similar to the NMDA receptor in that it 
is an excitatory receptor and is one of the 
most abundant types of receptors in the 
CNS.83 The AMPA and NMDA receptor
both have a tetrameric structure that is 
depicted in figure 4.85 The exact roles of 
AMPA receptors have not been 
completely elucidated.83 However, it is 
known that AMPA receptors are 
extremely fast excitatory receptors that 
serve a similar, although quicker, role as 
NMDA receptors in regards to signa
propagation.83 
The GABAA receptor is a 
heteropentameric receptor that spans the 
membrane four times while the GABA
receptor is a heterodimeric receptor that 
spans the membrane seven times.
GABAA receptor is an ionotropic 
receptor, meaning it permits ion influx 
when bound to its ligand, specifically 
chloride or bicarbonate ions.73 The 
GABAB receptor is a G-protein coupled 
MDA receptor is that it is blocked by magnesium ions 
82–84
 This does not typically 
83
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Figure 4: The Effects of Normal and 
Activation of the NMDA Receptor
of calcium influx resulting from normal and 
excessive activation of the NMDA receptor (b). 
The binding of glutamate and glycine for 
excessive periods of time can induce calcium
mediated neurotoxicity. The theorized tetrameric 
structure of the NMDA receptor embedded 
within the membrane is also accurately depicted 
in part b. The far left image of part a shows the 
NMDA under normal conditions. The middle and 
right images show the NMDA receptor under 
rapid (tetanic) and excessive stimulation 
respectively. Rapid and excessive stimulation 
results in the removal of magnesium ions that 
block the pore of the NMDA receptor.
excessive stimulation of the NMDA receptor 
results in large calcium influx that promotes cell 
death through the activation of apoptotic 
cascades.  The AMPA receptor has a very similar 
structure to the NMDA receptor.85 
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Excessive 
. The levels 
-
 Lastly, 
receptor.73 When a ligand binds to 
the GABAB receptor it activates a 
G-protein that goes on to turn on an 
effector.73 An excellent figure 
showing the differences between 
the GABAA and GABAB receptor 
can be seen in figure 5.73 
 As mentioned above, the 
GABAA receptor is made up of five
protein subunits to form an ion 
channel that is selectively 
permeable to chloride and 
bicarbonate ions.73 Each subunit of 
the receptor contains four 
hydrophobic alpha-helices that 
span the membrane.73 The C and 
termini  are located on the 
extracellular surface of the cell 
membrane.73 However, there is a large 
intracellular loop that contains 
phosphorylation sites that are important 
in regulating the receptor.73 
 
Discussion 
Commonly used general 
anesthetics in pediatric practice all affect the GABA
arguably the most important receptor to discuss when evaluating how general anesthetics may 
Table 1 
Effects of General Anesthetics on 
a. Volatile anesthetics 
Isoflurane 
Nitrous oxide 
Sevoflurane 
b. Intravenous anesthetics 
Ketamine 
Propofol 
 
Table 1: +++ represents activation and 
relevant concentrations. +/0 represents a small activation while 
inhibition of the receptor at clinically relevant concentrations. 0 represents no
concentration.83 
 
N 
A to some extent. Therefore, it is the 
Ligand-gated Ion Channels. 
GABAA AMPA  NMDA 
+++ --- -/0 
+++  -/0 --- 
+++  unknown unknown 
GABAA AMPA NMDA 
+/0 0 --- 
+++  -/0 -/0 
--- represents inhibition of the receptor at clinically 
-/0 represents a small 
 effect at any 
Figure 5: The Structure of the GABA
GABAB receptor. This figure depicts the 
and GABAB receptor embedded in the plasma 
membrane along with their relative structures and 
modes of activation (voltage change in part a and 
secondary messenger in part b).73 
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affect 
neurodevelopm
ent. However, 
the importance 
of the AMPA 
and NMDA 
receptors in 
neurodevelopm
ent is significant 
as well. 
Additionally, 
the AMPA and 
NMDA 
receptors are 
A and 
GABAA 
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affected by activation of the GABAA receptors especially during early development. Due to the 
complex interactions of these receptors, it is important to understand how general anesthetics 
affect all these receptors to fully elucidate the negative effects of general anesthetics on 
neurodevelopment. Evidence from animal and in vitro studies suggest that general anesthetics 
affect neural network formation causing potentially life-long negative effects on learning and 
memory. This is most likely due to the widespread inhibition caused by general anesthetics 
resulting in increased apoptosis. 
A table displaying the current scientific consensus, which is supported by a multitude of 
studies, on how five commonly used general anesthetics in pediatric care act on important and 
widely distributed receptors in the CNS can be seen in table 1.83 The AMPA, NMDA, and 
GABAA receptors are all affected by general anesthetics although every general anesthetic does 
not affect each receptor. Isoflurane inhibits AMPA receptors to the greatest extent followed by 
nitrous oxide and propofol. Isoflurane, nitrous oxide, propofol, and sevoflurane activate GABAA 
receptors to the greatest extent while ketamine only slightly activates. Nitrous oxide and 
ketamine inhibit NMDA receptors to the greatest extent while isoflurane and propofol only 
slightly inhibit. 
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Chapter 3: Proposing a Clinical Trial in Infants 
 
Introduction 
In 2007, the FDA investigated the long-term neurological effects of general anesthesia on 
infants due to concerns over neurotoxicity.26 They concluded that clinical studies should be 
conducted expediently to determine conclusively which general anesthetics should and should 
not be administered to infants 26. Infants are especially vulnerable to neurotoxins due to the 
extensive amount of neurodevelopment taking place during the first years of life. One critical 
period of neurological development, known as synaptogenesis, is severely hindered by general 
anesthetics. The human brain undergoes synaptogenesis from approximately the second trimester 
of pregnancy to three years after birth.21,25,28 Experiments on infant animals have shown that 
general anesthetics negatively influence neurological development.9,10,28 There is a desperate 
need for more information about general anesthetic safety considering the vulnerability of infants 
and their frequency of general anesthesia exposure due to non-elective surgery. 
The developing brain must be properly stimulated in order for neurological development 
to take place. Without proper stimulation, neurons within neural networks will undergo apoptosis 
in an effort to remove unneeded or unused connections.28 General anesthetics alter the 
stimulation of two vital receptors, NMDA and GABA.2,4–8 NMDA and GABA receptors are 
crucial in the formation of neural networks, stimulating neuronal migration, establishing firing 
patterns necessary for coherent thought processes.2,4–8,39,40 Early formation of neural networks 
and neuronal migration have long-term effects on memory and learning.2,4–8 Additionally, while 
it is not clear why some general anesthetics are less detrimental to neurological development, our 
study aims to elucidate more information on the relative safety of general anesthetics. Animal 
studies have demonstrated that early exposure to general anesthesia during neurodevelopment 
has more pronounced negative effects.14,17,25 
 
How General Anesthetics Induces Apoptosis 
A strong signal for a cell to undergo apoptosis is caspase-3 activation.86–88 Caspase-3 is 
activated through the actions of cytochrome c.86–88 Cytochrome c is released from mitochondria 
due to an increase in permeability of the mitochondrial membrane.86–88 One signal that increases 
mitochondrial membrane permeability is large influxes of calcium into mitochondria.86–88  
Several in vitro and in vivo studies have shown that exposure to general anesthetics induce 
neuroapoptosis through caspase-3 activation.89–95 Two in vitro studies on  mice and human 
neurons showed that exposure to clinically relevant levels of isoflurane increased levels of 
cytochrome c.89,96 
There are several proposed mechanisms that could explain why isoflurane causes the 
release of cytochrome c leading to caspase-3 activation. Some studies have indicated that 
isoflurane can directly interact with the mitochondrial permeability transition pore (mPTP) 
causing it to open.97,98 mPTP opening allows cytochrome c to be released subsequently inducing 
neuroapoptosis.86–88 Magnesium and propofol are both mPTP blockers.97,98 Two studies showed 
that magnesium and propofol are effective at blocking isoflurane-induced mPTP opening, 
reducing caspase-3 activation, and inhibiting neuroapoptosis in vitro in human neurons and in 
vivo in mice.97,98 This is one example of how a GABA agonist can increase calcium 
concentrations inside the cell induce neuroapoptosis. The NMDA antagonist ketamine also 
affects mitochondrial membrane permeability causing cytochrome c to be released.99 This has 
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led many experts to believe that many general 
anesthetics induce apoptosis in this fashion.99 
The results of this experiment are shown and 
explained in figure 6.99 Isoflurane has other 
potential mechanisms by which it can induce 
apoptosis such as altering calcium.  
Calcium plays a major role in cell 
signaling and the inositol 1, 4, 5-triphosphate 
(IP3) receptor is a major route for mobilizing 
calcium stores in almost all cell types.100 The 
IP3 receptor is located on the endoplasmic 
reticulum (ER) that regulates calcium 
release.100 Due to the close proximity of IP3 
receptors and mitochondria, over-activation of 
the IP3 receptor causes calcium depletion in the 
ER and calcium uptake in mitochondria.100,101 
Therefore, over-activation of the IP3 receptor 
can induce caspase-3 activation and cellular 
apoptosis by increasing mitochondrial 
membrane permeability.86,87,100,101  In vitro 
studies have shown that isoflurane increases 
intracellular calcium levels in rat neurons.102,103 
One study on rat neurons showed that 
isoflurane at clinically relevant concentrations 
interacts with the IP3 receptor.103 This 
interaction causes calcium dysregulation that 
induces neuroapoptosis.103 Moreover, 
isoflurane did not induce apoptosis in neurons 
that lacked IP3 receptors at any concentration 
or length of exposure.103 Two in vitro studies 
have shown that compounds that block IP3 
receptor activity inhibit isoflurane-induced 
apoptosis.103,104 Isoflurane also induces 
caspase-3 activation which is capable of 
triggering additional calcium dysregulation.89–
95
 Caspase-3 activation can cleave IP3 
receptors causing permanent calcium leakage 
from the ER.104 Figure 7 shows the different 
pathways that can lead to an imbalance of 
calcium and induce cellular apoptosis.51  
Inhibition of the NMDA receptor 
causes neurons containing this receptor to 
compensate by increasing NMDA receptor 
expression.27 Upon relief of inhibition, these 
neurons typically have too much calcium 
influx due to activation of an excessive amount 
Figure 6: Results of Neuron Exposure to 
Ketamine. A. Neurons exposed to ketamine 
had increased mitochondrial membrane 
permeability. B. Not relevant to the topic 
being discussed. C. DAPI staining was used 
to visualize nuclear DNA (shown in blue) 
while mitochondria were tagged with a 
green fluorescence protein (shown in green). 
D. Cytochrome C localization was analyzed 
using an immunofluorescence staining 
(shown in red). The merged images clearly 
depict that ketamine treatment results in a 
cytochrome C exiting the mitochondria 
(where they are present in normal cells) and 
instead localizing in the cytosol where they 
can induce apoptosis.99 
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of NMDA receptors. 
This can lead to apoptosis through cytochrome c release from the mitochondria. This 
appears to be the main mechanism by which general anesthetics that are NMDA antagonists 
induce apoptosis.27 However, as demonstrated by isoflurane, there may be other unknown 
mechanisms by which NMDA receptor antagonists or GABA receptor agonists that contribute to 
general anesthetic neurotoxicity. For example, ketamine is a NMDA antagonist that also causes 
cytochrome c release. 
 
Animal Models and Clinical Trials 
There is mounting evidence 
that general anesthetics used in 
pediatric care are damaging to the 
developing brain. General 
anesthetics act through NMDA 
antagonism and/or GABA 
stimulation have been show to 
induce apoptosis in the developing 
rat brain.105 Studies on infant mice 
and rats have shown that NMDA 
blockade or GABA over-activation 
for hours at a time increases the rate 
of neuroapoptosis in the developing 
brain.9–16 Several anesthetics have 
been shown to induce apoptosis in a 
dose dependent manner including: 
propofol, isoflurane, and ketamine.9–
16,27,106
 Normally, the brain 
undergoes periods of intense 
neuroapoptosis during development 
in order to remove extraneous 
connections and strengthen neural 
circuits. 28 The increase in 
neuroapoptosis during development can lead to life-long learning disabilities.28 This is most 
likely due to the loss of connections that are necessary for the proper functioning of important 
neuronal circuits. Dendritic spines are also drastically altered in structure upon exposure to 
general anesthetics.46,47 Dendritic spines are necessary for proper synapse formation and 
function.46,47 The loss of dendritic spines can lead to problems with learning and memory dud to 
gaps in neural networks. 46,47  
A group of researchers looked at how isoflurane affected dendritic spines. They found 
that exposure to isoflurane caused a reduction in dendritic spines.47 However, the addition of the 
proteases plasmin and tissue plasminogen activator (tPA) were both shown to reduce the 
isoflurane-induced reduction of dendritic spines.47 tPA is the protease that converts plasminogen 
to plasmin.47 Plasmin and tPA, through their effects on plasmin levels, affect the concentration of 
a ligand called pro-brain derived neurotrophic factor (pro-BDNF).47  Pro-BDNF is converted to 
mature BDNF by plasmin.47 Pro-BDNF is capable of binding to a receptor that induces 
apoptosis, the p75NTR receptor.47 Isoflurane reduces the levels of tPA released by decreasing 
Figure 7: Calcium Dysregulation and Apoptosis. 
The Bcl-2 protein controls calcium homeostasis by 
interacting with the IP3 receptor. Excessive release of 
calcium from ER through the IP3 receptor increases 
mitochondrial membrane permeability. This allows 
cytochrome c to be released and activate caspase-3. 
Caspase-3 induces apoptosis and cleaves the IP3 
receptor leading to permanent calcium leak from the 
ER.51 
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neuronal activity through over-activating GABA receptors. tPA is released in response to 
neuronal activity.47 Studies using animal models have shown that BDNF is important for 
promoting neuronal growth, survival, and differentiation.107 This is one potential mechanism by 
which isoflurane may promote neuroapoptosis. A figure depicting the results of the study can be 
seen in figure 8.47 
There is evidence to suggest that a 
combination of general anesthetics, 
particularly those that act primarily on 
different receptors, are more detrimental 
to neurodevelopment.10,16,17,105 A study 
looked at the effects of clinically relevant 
exposure of rats to midazolam, nitrous 
oxide, and isoflurane for six hours.105 
Nitrous oxide acts as an NMDA 
antagonist, causing inhibition. However, 
isoflurane acts as a GABA agonist, 
causing inhibition. Nitrous oxide acts as a 
GABA agonist as well (albeit to a slightly 
lesser degree). Wide-spread apoptosis in 
the developing brain of these rats 
suggests that exposure to a combination 
of general anesthetics that act primarily 
on different receptors is more detrimental 
than exposure to a single anesthetic 
agent.105 This is an agreement with 
studies in other animal models. 
Furthermore, this study showed that the 
infant rats that were exposed had spatial 
learning and memory deficits as 
adolescents and adults compared to 
controls.105 Besides a negative 
combinatorial effect, there is evidence 
that multiple exposures to general 
anesthetics is much more detrimental 
than a single exposure. One study 
showed that apoptosis in neurons was 
elicited in infant rats after repeated 
exposure to ketamine over a nine hour 
period.106 This study is just one of many 
studies that demonstrates that repeated 
exposure to general anesthetics is more 
detrimental than a single exposure.12,43,106 
Several studies using infant 
rodents and primates have revealed that the greatest damage to neurodevelopment induced by 
general anesthetics is during periods of peak synaptogenesis.9–16,108 The infant brain undergoes 
periods of synaptogenesis from the second trimester of pregnancy to around three years of 
Figure 8: Dendritic Spine Density. Slides of 
neonatal primary neurons in vitro using drebrin 
immunofluorescence microscopy (part A and B). 
The primary neurons were exposed to isoflurane 
for 4 hours at a concentration of 1.4% (clinically 
relevant) and subsequently stained 2 hours later 
for debrin and doublecortin. Isoflurane exposure 
reduced levels of drebrin (shown in green) 
expression in the primary neurons. Yet, 
doublecortin (shown in red) expression levels 
were not affected. Plasmin and tPA were 
administered to the neurons and significantly 
reduced the loss of dendritic spines induced by 
isoflurane. The neurons were also stained with 
DAPI (shown in blue) to highlight nuclear DNA. 
Areas of overlap appear as combinations of the 
colors mentioned. The quantification of the data 
can be seen in part C.47 
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age.21,25,28–30 Virtually all of the brain undergoes increased neuronal growth throughout the 
period of synaptogenesis with the growth of various areas, such as the temporal and frontal lobe, 
peaking at different points.27 This could contribute to the difficulty in evaluating the detrimental 
of effects of general anesthesia in a clinical setting on infants and should be taken into 
consideration.  
One of the main concerns many experts have with the current research done in animal 
models is clinical translation.37 The timing of development and exact clinically relevant 
concentrations of general anesthetics are difficult to standardize and extrapolate when working 
between species.37 However, this concern does not change the fact that the most current research 
at a minimum warrants that clinical trials in infants be conducted. It is time for an answer 
concerning whether general anesthetics are safe for the infant brain. 
There are several studies that have tracked and directly assessed infant development 
following surgical repair. However, none of these studies recorded the concentration or duration 
of general anesthesia exposure. Additionally, many of the studies did not address confounding 
factors, making their results irrelevant to the current topic.107 Yet, there are studies that have 
utilized the digitization of medical records to track the development of large cohorts of children 
exposed to general anesthesia in retrospective and epidemiological studies. 
Many retrospective studies on human infants show a correlation between exposure to 
general anesthesia and an increased risk of neurodevelopment disorders especially in learning 
and memory.18–25 Learning and memory deficits are consistent with data from animal models.105 
Animal studies on the effects of general anesthetics on neurodevelopment have shown that the 
hippocampus is the area of the brain that is most severely affected.27 The hippocampus is one of 
the most important areas of the brain in regards to learning and memory formation. Also, the 
NMDA receptor is known to be vital to learning and memory.32 The agreement of clinical trials, 
extensive studies using animal models, and in vitro experiments is strong evidence that general 
anesthetics affect learning and memory development in some form or fashion. 
Unfortunately, the types of retrospective and epidemiological studies performed thus far 
are statistically limited due to confounding factors. Unfortunately, a correlation is usually not 
enough to cause changes in clinical practice. Causation is the gold standard that must be 
achieved before the scientific community can come to a consensus that eventually leads to 
changes in clinical practice. Regardless, the results of these studies are still concerning and 
should be taken very seriously considering their possible implications. For example, one study 
that evaluated children exposed to general anesthesia before age three found that they had 
reduced language and cognitive development even after one exposure.109 Several studies have 
also found that young children exposed to anesthesia have chronic behavioral irregularities that 
last up to one month after exposure.18,25,109–112 This occurs in up to 50% of young children that 
receive general anesthesia.18,25,109–112 The most common behavioral abnormalities include 
irritability, anxiety, and insomnia.25,112,113 Unsurprisingly, the younger the child is at the time of 
exposure results in more pronounced behavioral irregularities.25,112,113  
Interestingly, regional anesthetics are being evaluated for their safety in clinical practice 
in order to reduce or eliminate the need for general anesthetics during procedures. Regional 
anesthetics are similar to local anesthetics except that they block pain signals over relatively 
large portions of the body. While local anesthesia is typically administered to the tissue 
surrounding the desired site, regional anesthesia is administered to bundles of nerves or even the 
spinal cord to deliver broad nerve blockade over a relatively large portion of the body. 
Dexmedetomidine is a regional anesthetic being evaluated due to its minimal side-effects.114 It 
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can be used in conjunction with general anesthetics to reduce dosage requirements.114 Other 
regional anesthetics are being looked at for similar reasons.114 One study evaluated the outcomes 
of over 5,000 births to determine the effects of giving birth under regional or general anesthesia. 
The study concluded that mother’s that received regional anesthesia during childbirth had 
children with fewer instances of learning disabilities than those who received general 
anesthesia.110 However, the process of proving the safety of these regional anesthetics takes time 
and the results of these studies are far off. Therefore, it is important to evaluate the safety of a 
variety of drugs used to achieve anesthesia in case the safety of some proves to be questionable 
and are no longer used in practice. Withholding anesthesia altogether is not an ethical option due 
to known detrimental effects of severe stress or pain on neurodevelopment.107 Severe stress or 
pain drastically increases neuroapoptosis, stress hormones, pain tolerance, and instances of 
aberrant behavior.107 
 
Human Stem Cell Model Design 
This trial will employ the use of an in vitro human stem cell model made up of neural 
stem cells (NSCs) to study neurodevelopment. As mentioned above, general anesthetics have 
been shown to be most detrimental during times of intense synaptogenesis. The developing brain 
goes through intense synaptogenesis until the age of two.115 There has been great success in 
experiments using neural stem cell models to evaluate the effects of various drugs on the 
developing brain.53 NSCs can be acquired from infant and adult nervous tissue.53 The ability to 
derive these cells from adults makes the acquisition and use of these cells less controversial and 
more universally accepted. Embryonic mouse fibroblasts will be used as feeder cells to ensure 
the NSCs remain viable in vitro.53 A transmission electron microscope will be employed to 
evaluate the level of synaptogenesis and neural network formation throughout the duration of the 
experiment.53 The transmission electron microscope will also be used to evaluate the 
ultrastructure of the NSCs to visualize any abnormalities in organelles or cell structure upon 
exposure to general anesthetics agents.53 
The employment of an in vitro human stem cell model has several unique advantages. It 
is an ethical manner to obtain experimental data that has high translation to in vivo human 
neurodevelopment. The use of NSCs ensures that a virtually unlimited supply of cells can be 
maintained for exhaustive research opportunities. Additionally, the in vitro nature of the model 
allows tight control of experimental parameters, such as concentration of general anesthetic 
exposure. By avoiding animal sacrifice, NSCs can be evaluated more directly and frequently in a 
cost-efficient manner. This model has the potential to elucidate the molecular action of 
individual general anesthetics due to the several advantages mentioned above. 
In order to properly set up the neural stem cell model, a chemically defined a media is 
needed. The protocol described in Bai and Bosnjak will be used to ensure that iPSCs differentiate 
properly into mature neurons.113 This process is described in more detail in figure 9.116 The 
media helps to mimic the in vivo conditions of the brain causing neural stem cells to differentiate 
into several neuronal lineages including neurons, oligodendrocytes, and astrocytes.113 This model 
has been effective in producing functional synapses that mimic in vivo synapses.117 This model 
has proven it to be quite efficient in causing neurons to undergo differentiation. One study 
achieved 90% differentiation of cells into NSCs using this model.99  
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 The NSCs will be exposed to 
sevoflurane, propofol, ketamine, 
isoflurane, and nitrous oxide, the 
most commonly used general 
anesthetics currently used in infants. 
The dosage to which NSCs will be 
exposed to will vary between 
anesthetic agents. However, all 
agents will be evaluated at .5, 1, 2, 
and 4 times the clinically 
recommended concentration. 
Experiments will be conducted at a 
duration of 1, 2, 4, or 8 hours of 
general anesthetic exposure. The 
frequency of exposure to each 
general anesthetic will be 1, 2, or 3 
times. Controls will not be exposed 
to the general anesthetic agent. 
However, they will be exposed to all 
the same conditions with only the 
carrier gas used to deliver the 
individual anesthetic agents.  
A variety of assays will be 
used in conjunction with the 
transmission electron microscope to 
obtain a better idea of how 
general anesthetics may cause 
neurotoxicity. Cellular 
proliferation will be evaluated 
using bromodeoxyuridine (a 
thymidine analog that gets 
incorporated into newly 
formed DNA) and Ki67 (a 
non-histone, nuclear protein 
that is not expressed in 
dormant cells).53 Cell viability 
will be measured using an 
LDH and MTT assay. A 3-
(4,5-dimethyithiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide 
(MTT) dye is used to measure 
mitochondrial function and 
cell viability.118 The MTT dye 
is degraded by mitochondrial 
dehydrogenase activity, 
producing a colored 
Figure 9: Neural Stem Cell Model. This figure depicts 
how human embryonic stem cells (hESCs) can be induced 
to differentiate into various types of neurons in a four step 
process that is translatable to iPSCs. The fours step process 
causes hESCs to differentiate into embryoid body 
formations, neural rosette cells, neural stem cells, and 
various types of neurons in that order (part A). Stem cell 
markers are shown in pink and green in part b and c to 
indicate differentiation is starting to occur. In parts d and e, 
nuclear DNA is shown in blue and a neuroepithelial marker 
is shown in green (only part e), indicating the hESCs had 
developed into embryoid bodies. In part g, a biomarker 
specific to neural stem cells is shown in red, indicating the 
embryoid bodies have differentiated into neural stem cells. 
In part C, the cells have fully differentiated into neurons and 
are expressing two biomarkers specific to neurons, β-tubulin 
III shown in green (part b) and MAP2 which is also shown 
in green (part c). Additionally, the neurons expressed two 
biomarkers specific to synapses, synapsin-1 shown in red 
(part d) and Homer 1 shown in green (part e).116 
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product.118 This concentration of this colored product will then be quantified using a 
spectrophotometer. Lactate dehydrogenase (LDH) is an enzyme that can pass through the 
cellular membrane if it is damaged.118 The concentration of LDH in culture will be quantified 
using an LDH assay to determine the amount of cells that are damaged or nonviable.118 Real-
time PCR will also be employed to elucidate which genes are over- or under-expressed upon 
general anesthetic exposure. RNA will be extracted from experimental and control cells. This 
RNA will be reverse transcribed and amplified using PCR. The resulting cDNA will be run 
through a database and quantified to determine levels of gene expression.118 
It is believed that the primary mechanism of neurotoxicity by general anesthetics is 
increased apoptosis.118 DNA fragmentation can be visualized using terminal deoxynucleotidyl 
transferase-mediated deoxyuridine triphosphate in situ nick end labeling (TUNEL) staining. 
DNA fragmentation is indicative of cellular apoptosis.118 The level of DNA fragmentation will 
be recorded using a confocal microscopy to quantify the amount of cells going through 
apoptosis.118 A caspase-3 colorimetric assay will also be used to quantify the number of cells 
going through apoptosis.118  
This model has been used to effectively evaluate the neurotoxic effects of ketamine and 
isoflurane individually. Both studies found that prolonged exposure to either general anesthetic 
increased neuroglia cell proliferation and neuronal apoptosis.99,116 Isoflurane and ketamine both 
caused apoptosis by increasing cytochrome c and reactive oxygen species levels.99,116 While the 
concentration and duration of general anesthetic exposure were outside of clinical relevance, 
these studies do show that a neural stem cell model is an ideal method for evaluating how 
general anesthetics influence cellular processes inducing apoptosis in vitro. 
 
Clinical Trial Design 
Participants will be selected from a pool of infants that are two years of age or younger 
that are requiring surgery for issues unrelated to neurodevelopment. The age was decided to 
correlate with the critical neurodevelopmental period of synaptogenesis. Synaptogenesis occurs 
in the human brain from the time of birth to approximately three years of age.37 During surgery, 
the general anesthetic(s) used will be recorded along with the concentration and duration of 
exposure. Other drugs used and any complications during surgery will also be noted. Participants 
will receive free-of-charge anesthesia upon commitment to assessments of cognitive and 
behavioral development every other year for eight years. Assessments every other year will 
allow a greater range of development to be assessed for a more cost-effective approach. The 
assessments will be based on the outcome of the neural stem cell experiment as well as previous 
clinical trial conclusions. 
The assessments employed will be the Wechsler Abbreviated Scale of Intelligence 
(WASI) and NEuroPSYchological Assessment, second edition (NEPSY II). WASI will be used 
to evaluate global cognitive function by determining global IQ and verbal skills.119 NEPSY II 
will be used to evaluate specific cognitive functions.119 A behavioral assessment will be 
conducted by providing the Child Behavior Checklist ages 2-10 to the parents.119 The sibling of 
participants will perform identical assessments with the same professional at the same age as 
their sibling. Age-specific instruments will be used during the assessments to reduce statistical 
variability and potential error.26 This will not be an issue since siblings will perform identical 
assessments at the same age as their sibling that was exposed to general anesthesia. Sibling-
pairing has been shown to be an effective method for reducing confounding factors because 
inter-sibling differences are minimal in comparison to random selection.26 We hypothesize that 
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depending on the age of exposure different areas of the brain will be affected, producing a slight 
variation of symptoms. This is based on the fact that synaptogenesis peaks at different times in 
different areas of the brain.27 However, we also hypothesize that learning and memory will be 
affected the most, which would agree with current data from animal model studies.27 
 
Discussion 
There is a drastic need for more information about the safety of using general anesthetics 
in infants. Too many infants are being exposed to potentially neurotoxic agents that could have 
devastating effects on neurodevelopment. Unfortunately, while the evidence suggests that 
general anesthetics could be neurotoxic, the lack of consensus by the medical community has 
prevented any changes in clinical practice from occurring. 
The critical periods of brain development are important in the synaptogenesis in the 
formation of neural networks.  However, during this critical time period, neuronal stem cell 
proliferation, neuronal migration, and the formation of axons and dendrites also occurs within 
this time.113,120,121 Therefore, general anesthetics have the potential to affect several 
neurodevelopmental processes.113,120,121 These neurodevelopmental processes can be stimulated 
in neural stem cells, providing an ideal model for evaluating general anesthetic neurotoxicity in 
vitro.113 An additional benefit of using neural stem cells is that they can replicate the phenotype 
of a patient with an heritable disease.113 Assuming the in vitro neural stem cell model is effective 
in the trial proposed, it could capture the interest of researchers and lead the utilization of stem 
cells in future studies. This stem cell model would be a useful method for carefully and 
repeatedly evaluating how genetic factors influence pathology. One of the only downsides of this 
technology is that the results of studies cannot be directly translated to a true in vivo system. 
However, this is a fault that is necessary due to the nature of in vitro studies. The current study 
would greatly benefit if stem cell technologies were capable of culturing many types of neurons 
to gather to more accurately mimic the conditions of an in vivo brain. As new technologies 
emerge and interest grows, future studies could utilize this type of stem cell model to produce 
more conclusive and translatable data. 
This study is unique and provides valuable contributions to the field in several ways. 
First, this will be one of a few studies to evaluate the neurotoxicity of general anesthetics using 
the in vitro neural stem cell model. Second, this is the first clinical trial to evaluate general in 
anesthetics in vivo and in vitro simultaneously. Third, this is currently one of the first studies 
directly assessing neurodevelopmental outcomes of children exposed to general anesthetics as 
infants using sibling-paired controls. Lastly, no other study has evaluated the number of general 
anesthetics we will be evaluating using the in vitro neural stem cell model. 
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